Drug Profile
Enadenotucirev - Akamis Bio
Alternative Names: Ad11/Ad3 chimeric group B adenovirus; ColoAd-1; EnAd; Oncolytic Ad11/Ad3 chimeric group B adenovirusLatest Information Update: 05 Jul 2023
Price :
$50
*
At a glance
- Originator PsiOxus Therapeutics
- Developer Akamis Bio; Bristol-Myers Squibb; Merck & Co; University of Oxford
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Renal cancer; Urogenital cancer
- No development reported Cancer; Head and neck cancer; Ovarian cancer; Salivary gland cancer; Solid tumours
Most Recent Events
- 24 Feb 2023 PsiOxus Therapeutics completes a phase I trial for Colorectal cancer (Metastatic disease; Late-stage disease) in United Kingdom (NCT03916510)
- 05 Jan 2023 PsiOxus Therapeutics is now called Akamis Bio
- 28 Aug 2022 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Metastatic disease) in United Kingdom (IV)